PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    San-Miguel JF (1), Echeveste Gutierrez MA (2), Špicka I (3), Mateos MV (4), Song K (5), Craig MD (6), Bladé J (7), Hájek R (8), Chen C (9), Di Bacco A (10), Estevam J (10), Gupta N (10), Byrne C (10), Lu V (10), van de Velde H (10), Lonial S (11).

    (1) Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA), El Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
    (2) Hospital Universitario Donostia, San Sebastián, Spain.
    (3) 1Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
    (4) Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain.
    5 Division of Hematology, University of British Columbia, Vancouver, BC, Canada.
    (6) Department of Medicine, West Virginia University, Morgantown, WV, USA.
    (7) Department of Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain.
    (8) Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, Ostrava University, Czech Republic.
    (9) Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, ON, Canada.
    (10) Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
    (11) Winship Cancer Institute of Emory University, Atlanta, GA, USA.

    Haematologica 01 de SETEMBRO de 2019

  • A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

    Márquez-Rodas I (1,2), Arance A (3), Berrocal A (4), Larios CL (5), Curto-García J (5), Campos-Tapias IX (6), Blanca AB (6), Martin-Algarra S (7).

    (1) Medical Oncology, Hospital General Universitario Gregorio Marañón, Calle Dr. Esquerdo 46, 28007, Madrid, Spain.
    (2) CIBERONC, Madrid, Spain.
    (3) Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain.
    (4) Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.
    (5) Clinical Research Department, MFAR S.L, Barcelona, Spain.
    (6) AMGEN S.A, Barcelona, Spain.
    (7) Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain.

    Clinical & Translational Oncology 21 de AGOSTO de 2019

  • A novel concept to include uncertainties in the evaluation of stereotactic body radiation therapy after 4D dose accumulation using deformable image registration

    Azcona JD (1), Huesa-Berral C (1,2), Moreno-Jiménez M (3), Barbés B (1), Aristu JJ (3), Burguete J (2.)

    (1) Service of Radiation Physics and Radiation Protection, Clínica Universidad de Navarra, Avda. Pío XII, 36. 31008, Pamplona, Navarra, Spain.
    (2) Department of Physics and Applied Mathematics, School of Sciences, Universidad de Navarra. C/ Irunlarrea, 1. 31008, Pamplona, Navarra, Spain.
    (3) Service of Radiation Oncology, Clínica Universidad de Navarra, Avda. Pío XII, 36. 31008, Pamplona, Navarra, Spain.

    Medical Physics 11 de AGOSTO de 2019

  • Amylin as a potential link between type 2 diabetes and Alzheimer's disease

    Martinez-Valbuena I (1,2,3), Valenti-Azcarate R (1,2,3), Amat-Villegas I (3,4), Riverol M (1,3), Marcilla I (2,3), de Andrea CE (5), Sánchez-Arias JA (3,6), Del Mar Carmona-Abellan M (1,2,3), Marti G (1,3), Erro E (3,7), Martínez-Vila E (1,3), Tuñon MT (3,4), Luquin MR (1,2,3).

    (1) Neurology Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Regenerative Therapy Laboratory, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
    (3) Navarra's Health Research Institute (IDISNA), Pamplona, Spain.
    (4) Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (5) Pathology Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Small Molecule Discovery Platform, Molecular Therapeutics Program, CIMA, University of Navarra, Pamplona, Spain.
    (7) Neurology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.

    Annals of Neurology 03 de AGOSTO de 2019

  • A paradigm shift in bariatric surgery outcome evaluation?

    Unamuno X (1), Portincasa P (2), Frühbeck G (3).

    (1) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBEROBN, 31008 Pamplona, Spain.
    (2) Division of Internal Medicine "Augusto Murri", Department of Biomedical Sciences and Human Oncology, Policlinico Hospital, University of Bari "Aldo Moro", Bari, Italy.
    (3) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBEROBN, 31008 Pamplona, Spain. Electronic address: gfruhbeck@unav.es.

    Lancet Diabetes Endocrinology 02 de AGOSTO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra